TNFSF10 and type 2 diabetes mellitus: Moving to humans, clinical studies in patients with T2DM have shown that circulating serum TRAIL levels are reduced in newly-diagnosed T2DM patients [24], and they progressively increase after 6 months of antidiabetic treatment but remain still lower compared to non-diabetic control subjects even after treatment [30].